Information For Health Professionals
E-Cigarettes represent the best method yet to reduce the smoking-related death and disease rate, because they are a clean nicotine delivery system and reproduce the smoking experience better than any other product. Swedish Snus is the best proven safe and effective replacement for smoking , but Snus is not seen as anywhere near as popular by comparison. The target markets for e-cigarettes are older smokers who have failed in several quit attempts, and parents who want to keep their health and not subject their children to smoke; but it is likely that most smokers can successfully switch to an e-cigarette given the motivation, good resources and correct support.
The basic principal behind electronic cigarettes is Tobacco Harm Reduction: the replacement of a dangerous delivery system by a clean one. The harm is almost all caused by the smoke; remove the smoke and most of the potential for harm goes with it. For the vast majority of people, responsible consumption of nicotine poses no identifiable risk. There are no clinical trials or surveys that show responsible nicotine consumption over several decades has any elevated risk, and this can be clearly seen at population level from the Snus data. Indeed, the Snus data shows the opposite: long-term ad lib nicotine consumption is all but harmless.
What evidence is there that this approach works?
Sweden reduced their smoking prevalence by 50%, with the smoking-related mortality rate falling in parallel, due to smokers changing in large numbers to the specially-processed smokeless tobacco known locally as Snus. As a result they have the lowest smoking-related death rate in the developed world by a wide margin, understandable since they now have the lowest number of smokers: just 11% of the population at Q2 2013, and 8% among males – soon to become 5% by around 2016 as prevalence is still falling at 1% per year; this is a phenomenally low figure and absolutely unachievable by any other country under any circumstances (except full, unrestricted support for consumer THR). It’s known as ‘the Swedish Miracle’ in public health circles .
More than 150 clinical studies of Snus over more than 25 years with trials including tens of thousands of subjects demonstrate clearly that ad lib consumption of nicotine over decades has no statistically significant risk. The facts show the same thing: Sweden’s smoking-related mortality figures show an unprecedented reduction in the death rate (the lowest of any developed country by a wide margin, and about half the EU average). From this it can be seen that (a) this approach is not new, indeed it has been exceptionally successful for many decades, and (b) the evidence base for advocating this approach is extremely strong – in fact irrefutable.
We fully expect the take-up of e-cigarettes to be even higher than that of Snus in Sweden, since e-cigarettes are demonstrably more popular with smokers than Snus. It has been estimated that the free availability of e-cigarettes and Snus in a country such as the UK would reduce the smoking-related death rate by more than 50% .
The number of smokers has fallen substantially in most developed countries in the last two or three decades, due to education, high tobacco taxes, and an advertising blackout. Unfortunately that rapid fall has now bottomed-out and stalled at around one-fifth of the population (depending on how it is measured); any current fall is due to the substitution effect of e-cigarettes. There are no conventional measures left that will substantially reduce it further, and smoking prevalence is stuck around 20% (the average of the figure quoted by various organisations, which tends to vary between 18% and 22%, according to who the source is and how the figure was measured). There are even some reports that show the number of smokers has increased slightly in some areas (for example in Scotland).
Smokers themselves have now taken control
However, smokers themselves have now found a better option, and have already taken action that considerably outperforms all official health initiatives: in the US and UK we know that, at Q2 2013, more than 8% of smokers have already switched to an e-cigarette. ASH UK measured the number of UK ecig users at 310,000 in 2010, then 650,000 in early 2012; at Q2 2013 we estimate that more than 1 million smokers have switched to e-cigarette use.
We don’t know what the proportion is of e-cigarette users (and ex-ecigarette users of course) who no longer smoke; estimates vary from 10% to 50%. It certainly varies across the usergroup types, and in the vaping population as a whole may be around 33%. It appears that smoking prevalence reduction stalled at around 22% in the UK, and all subsequent reduction is due to the switch to e-cigarettes. Since more than 8% of smokers are now e-cigarette users, and since one-third are now non-smokers, it is reasonable to estimate that up to 3% of smoking prevalence reduction in the UK is due to e-cigarette uptake. Since 2010 enough smokers switched to vaping to make this visible at population level.
These ‘vapers’ now probably have the same expectation of risk as a Snus user – and a Snus user has the same risk as a non-smoker . The smokers’ own action has already clearly outperformed official action, and that difference will increase.
Commentators generally state that the main reasons for historic reduction in smoking prevalence was due to such things as education, high cost of smoking (i.e. taxes), and social pressure (denormalisation). Health interventions such as quit-smoking treatments never figure in these calculations as they are so tiny in scale. The percentage of ex-smokers who report that they were pharmaceutically assisted in their successful quit attempt is very small (the ‘cold turkey’ method is always demonstrated as around 70% in all surveys of successful ex-smokers and is at least 6 times more effective than pharmaceutical interventions in the real world). Therefore, if the current rate of smoking prevalence reduction in a given country (such as the UK) is an absolute maximum of 0.2% per year attributable to conventional methods of reduction (as it is), we could estimate that the effect of health service interventions would be less than 0.01%. This is not value for money when the UK cost of NHS quit smoking services (the national health service official programme including pharmaceutical interventions) is around £200m. In effect it is money down the drain – especially when compared with e-cigarettes, which have already shown sufficient smoking prevalence reduction in the UK to show they are far more effective than the official method – and at zero cost to the health service.
If e-cigarettes remain freely available and unobstructed, there is no reason why their effect should not equal and even overtake that of Snus in Sweden, which has reduced the number of smokers by 50%, with the number of smoking-related deaths falling toward the same level. As an example of the trends there, as Snus consumption increased dramatically in the last two decades, oral cancer rates fell dramatically. We can see that many disease vectors reduce substantially (or are even removed); although intuitively we might expect oral cancer rates to remain stable or even increase with Snus consumption, the facts are in opposition to the presumption, and Snus itself has no elevation of risk for oral cancer; thus oral cancer rates fall in proportion to the number of smokers who switch to Snus. (The main risks for oral cancer are smoking, drinking and HPV; Snus has no visible effect.)
In view of this predilection to the subconscious belief in propaganda to which we are all subject, it is worth re-examining each and every aspect of smoking related morbidity and mortality in relation to the facts: the epidemiologic data – and not press releases on ‘clinical studies’ from groups funded by commercial interests.
Do e-cigarettes work?
As a safer replacement for smoking, for long-term use, we know that e-cigarettes work. Several million people use them for that purpose (over 3 million in the USA and 1 million in the UK, and probably more than 3 million in the EU in total). Many people have successfully used them for several years. In the US, the annual market is worth up to $900m at Q2 2013, so we are not talking about a passing fad here – and the number of e-cigarette users grows by at least 1% of the smoking population per year.
As regards their use for ‘quitting’, if that means total quitting of cigarettes, tobacco, nicotine, inhalation and all use of leisure products in this class – we don’t have a clue, because nobody cares. Comparatively few people buy an e-cigarette for that purpose, there is no need – ecigs are an alternative, not a route to cessation. People buy an e-cigarette to keep smoking but without the harm.
No doubt quitting works for some but it is not an application which community or industry members either support or are much interested in. Such persons would also be hard to track by the usual community methods such as forums in any case, as they would disappear from view.
It has been suggested that research be carried out on this aspect of their ‘efficacy’, but from the point of view of everyone involved currently, this would be the most pointless waste of time and money imaginable. Why quit drinking coffee?
We know that e-cigarettes work, because several million people use them, and have been using them for years; the number of people using them grows by as much as 40% per year; and because in addition to their unusual popularity, multiple user groups have grown up around their use and advocacy: online communities, local groups, national organisations, and trade associations. This in itself is a phenomenon and could not occur if e-cigarettes did not work.
We don’t know anything about their usefulness for total quitting because very few are interested in such an outcome – it is an application suited particularly to those with medical conditions that require nicotine cessation (patients with cardiac issues?) and/or cessation of inhalation of extraneous materials (patients with emphysema?) – therefore it is up to the medical profession to investigate such a usage profile, since it has no relevance to the vast majority of the population (at least 99.9% of people have no medical reason to need to quit vaping).
The 7% zero-nic group
We know from multiple surveys within the community that about 7% of vapers at any given time are using zero-nicotine refills. That is, they are using an e-cigarette without nicotine. Since vapers routinely reduce their nicotine levels over time, the 7% group must be continually receiving new entrants, therefore it must be losing them at the same rate. It seems logical that such persons quit totally rather than return to smoking.
Why quit if risk is minimal?
Swedish Snus is proven by huge amounts of data over almost 30 years to have a health risk so small that it cannot be reliably identified, and it has been argued by some that e-cigarettes will have a similar or lower risk. There is no medical reason that can be seen at present to quit using an e-cigarette, since the health implications are likely to be found to be similar to coffee drinking. Ideally, no one would use consumer stimulants or stress relievers, but expecting total abstinence in the pressure-cooker environment of modern urban life is simply not reasonable.
As a concrete example of this fact-based approach to consumer Harm Reduction, let’s look at life expectancies.
- A smoker is believed to have an average reduction in life expectancy of around 10 years. There appears to be some debate about this, with figures of 6 years to 12 years given. (Doll et al gives 10 years.)
- A Snus user is shown by the 150 or so clinical studies to a have an average reduction in life expectancy of 4 weeks (from 2 weeks to 8 weeks is given by different sources). It can’t be too different from that of a coffee drinker.
This is the factual side of the argument: look at the epidemiology, not the press releases.
E-Cigarettes vs Snus
At an individual level, it seems fairly certain some will prove intolerant to some of the ingredients inhaled in ecig vapor, and may need to locate an acceptable refill liquid; it is even possibole that a few may not be able to find a tolerable refill. Emphysema and stage 4 COPD patients are another such group, and who are probably better off avoiding ecigs.
Such persons may need to find an alternative such as Snus, or quit. Since all the ingredients of e-cigarette refills with the exception of the flavorings are known to be harmless, and are used in medical applications for inhalation, we can be fairly sure there are no major surprises in store. In addition, it seems highly unlikely that chocolate flavor will cause thousands of deaths.
Therefore an e-cigarette can justifiably be seen as an acceptable replacement for smoking, and at this time it is hard to see a different outcome from that of Snus in the population-level proof of safety. There is no medical reason for quitting e-cigarettes, as a population-level measure. As always, individuals may need specific solutions.
The safety of e-cigarettes
There have been more than fifty research papers, surveys, clinical studies and clinical trials published on e-cigarettes. None show any real evidence of potential for harm. Since the main ingredients are also used in inhalable medicines and disco fog machines, this is hardly surprising. Fog machines are licensed under employment health and safety regulations for long-term high-volume inhalation duty by employees, and these regulations are both strict and impossible to pervert. There is 70 years of safety data on these materials in any case – we list around 40 references below .
Attacks on e-cigarettes
Trials paid for by commercial rivals, such as the pharmaceutical industry, tend to be published with admirable hyperbole – but the content of the press release is often at variance with the facts in the trial. A good example is the FDA’s famous press release and analysis of e-cigarette refills, where the hysterical text of the PR bore no relation to any facts discovered in the analysis. Indeed, the FDA’s e-cigarette trial demonstrated admirable safety standards.
Example 1 – FDA: “E-Cigarettes contain carcinogens.”
Full story: True – but at the same levels present in licensed NRTs (~8ng/gm) (as the same pharmaceutical grade nicotine is used, and it is not economic or practical to completely remove traces of contaminants that have no health implications). In the words of Prof Rodu, the leading authority on the oral pathology of tobacco consumption, “These levels are about a million times lower than conceivably harmful to health”; a fact well-known to the FDA as they license the ‘carcinogenic’ NRTs.
Example 2 – FDA: “E-Cigarettes contain antifreeze.”
Full story: True – but so do the nebulisers used by lung-transplant patients. The ‘antifreeze’ in question, propylene glycol, is a non-toxic virtually inert material that works very well as a carrier for other materials (such as medicines or nicotine), with an extremely low freezing point, that is cheap to manufacture at industrial grade, and which possesses an extraordinary potency as a bactericide and virucide when dispersed as an aerosol. Since the pharmaceutical grade is injected into the bloodstream as the diluent for medicines such as diazepam, and breathed in by lung transplant patients, its potential for harm is presumably not too great. The use of industrial-grade PG as a specialist non-toxic antifreeze and virucide for use in applications such as air-conditioning plants in order to prevent Legionnaire’s Disease is hardly relevant – a fact well-known to the FDA as they license it for the medical uses.
The reliability and truthfulness of the FDA can be easily judged from these examples; one professor of public health medicine described them and their ilk as “crooks and liars”. At this point it may be prudent for sceptics to investigate the concept of Regulatory Capture. It might be questioned whether the FDA always works for public health rather than apparently to protect the pharmaceutical industry.
Support for e-cigarettes
Many professors of medicine and public health experts have endorsed e-cigarettes. Their work is easily found by googling: profs. CV Phillips, B Rodu, M Siegel, J Britton, R West and others . Prof Siegel’s evidence was instrumental in obtaining the huge Master Settlement Agreement against the US tobacco industry, so it can be seen that such persons are not aligned with any pro-smoking or pro-tobacco agenda.
Doctor’s associations and groups have endorsed e-cigarettes:
AAPHP, the American Association of Public Health Physicians
ACSH, the American Council on Science and Health (whose physicians have been vociferous in denouncing the propaganda published against e-cigarettes)
RCP, the Royal College of Physicians, whose Tobacco Group chair Prof Britton said that if all UK smokers switched to an e-cigarette then 5 million lives would be saved just in those alive today.
The most well-known anti-smoking harm activist in the USA (and probably in the world), William T Godshall of Smokefree Pennsylvania, whose evidence has contributed to the success of many actions against the tobacco industry, fully endorses e-cigarettes. He attended a vapefest (a large-scale vaper’s meet of the convention type) in the US where hundreds of participants were available to inconvenience him with their exhaled vapor, and found no observed effect. He summarily dismissed a recent report paid for by the pharmaceutical industry that claims second-hand e-cigarette vapor causes throat constriction and dizziness , since he himself experienced no such effect in a room with 200 vapers enthusiastically providing air quality samples.
This is a considerable statement when it comes from Bill Godshall, probably the most committed anti-smoking harm campaigner in the world. Perhaps we can also add the title of ‘Most Honest’, as some colleagues do not seem to suffer from such an inconvenient attraction to the truth. Mr Godshall however is not funded by the pharmaceutical industry.
There is no research that shows responsible consumption of nicotine has any more health risk than drinking coffee. Nicotine does not cause the cancer and cardiovascular diseases caused by smoking.
However there are some individuals who would be wise to strictly limit their nicotine consumption – pregnant women and those with pre-existing heart disease for example.
It should be recognised that nicotine is a normal part of the diet and everyone tests positive for it either in the bloodstream or for metabolytes. This is why nicotine or cotinine tests for smokers have to have a minimum value delineated above which the person qualifies, since everyone tests positive at low levels (unless they eat no vegetables). The CDC in the US tested 800 people, all of whom tested positive, in order to validate the results of an earlier study in which 136 subjects all tested positive. It is possible however that if an individual avoids all vegetables, tea, ketchup and so on that they will be able to avoid nicotine, although this does not seem wise. Apart from other nutritional reasons, it is probable that nicotinic acid (vitamin B3 or niacin) would also be missing from the diet. This nutrient is co-located in vegetables and nutritional plants with nicotine, and can also be a nicotine metabolyte.
It is therefore more accurate to refer to ‘nicotine consumption’ as supra-dietary consumption: additional, larger amounts of a normal dietary constituent. Nicotine cannot be referred to in any way as an alien, toxic chemical or dangerous drug since it is a normal and natural part of the diet in small quantities – unlike caffeine or alcohol, which obviously qualify as more ‘alien’ since unlike nicotine they are not part of the normal, everyday diet. Like many such materials it is toxic in high doses since one of the main differences between a nutrient or medicine and a poison is simply the dose (c.f. vitamin D, vitamin A, iron, etc.).
All sorts of hysterical press releases, junk science and propaganda have been paid for by the pharmaceutical industry in their attempts to destroy what they see as a commercial rival. All these pseudo-scientific and quasi-medical efforts have been dismissed as junk science by professors of medicine who have actually carried out research into and investigations of e-cigarettes. As mentioned, the authors of such propaganda have been dismissed as “crooks and liars” by one professor of medicine and public health expert.
There is not one shred of evidence that e-cigarettes can cause harm or pose any substantial risk to health. If there were, the FDA and MHRA would have found it. They have looked very hard for such evidence and most likely expended substantial resources on such searches. Nothing was found, which is why the FDA lost in their court action in the USA against e-cigarettes, the judge clearly stating they had provided no evidence to show any potential for harm, never mind any recorded incident. The fact they have been used globally by millions of people for many years without incident was found relevant. This can be easily be compared with the safety record of a quit-smoking drug introduced at almost exactly the same time, Chantix, which is recognised by the FDA as having caused hundreds of deaths (272 officially admitted to at Q3 2012, although some say the real total is likely to be far higher); it also has a 1 in 30 risk of ‘cardiac event’ reported by several different independent clinical studies; and since it is demonstrated to have ruined thousands of lives, is therefore clearly shown to be thousands of times more dangerous than e-cigarettes.
Realistically, the only prospect e-cigarettes have for causing harm is in the area of minor lung issues. There will always be individuals who prove intolerant to one or other of the flavorings used. The other ingredients in an e-cigarette are used in asthma inhalers and the nebulisers used by lung transplant patients , so hardly pose a major threat (glycerine and propylene glycol, the principal excipients).
There is some question about the inclusion of contaminants in e-liquids. In general it is not in the interests of a business to poison its customers, so responsible vendors buy good-quality materials and carry out testing. In the UK, all materials are tested by the Trading Standards Institute’s local inspectors and no contamination has been found. The UK trade association, ECITA, own a GC-MS machine and have a professional chemist available for testing. It is in everyone’s interest if rogue traders are identified and shut down.
Some contaminants have occasionally been found in some samples elsewhere but these have all been shown to be insignificant or not relevant. For example one sample of liquid from 18 tested by the FDA showed very low level DEG contamination, but this was not detected in the vapor so is not of concern. Carcinogens are frequently detected but at the same level or lower than those in NRTs, which are assumed to be safe. If e-cigarettes are unsafe due to the carcinogens then all NRTs would presumably need to be withdrawn from the market immediately.
Of course this argument is ridiculous, since the long-term Snus data shows no elevated risk for any kind of cancer, despite the levels in Snus being considerably higher.
The emphysema / pneumonia issue
There is seen to be an issue with e-cigarettes and emphysema. We know that emphysema patients are at elevated risk of pneumonia, and it may be possible that use of an e-cigarette may exacerbate this.
Emphysema patients, and those with other forms of Stage 3 or Stage 4 COPD, should not use an e-cigarette – they should cease all forms of inhalation of non-necessary materials. This seems so obvious that it is strange if instances occur where a patient with a terminal lung disease has an issue with e-cigarettes, this should be either commented on or, especially, advanced as some sort of reason that ‘ecigs are bad’.
They are bad if you have emphysema, and nobody is arguing about that. Snus is probably the only acceptable consumer Harm Reduction product for patients with severely compromised lungs. There is too high a risk of pneumonia for these patients to continue inhalation of anything other than normal air or medical treatments for their lung diseases.
The drawbacks of e-cigarettes
1. Tolerance issues
It is impossible that all ingredients in all brands of e-liquid will be well-tolerated by all individuals. The most likely problems that may be encountered are minor lung irritation issues that can be resolved by changing to a brand with a different ingredient profile. Some individuals may tolerate glycerine as the excipient better than propylene glycol, and some vice-versa. Some individuals may not tolerate some flavourings.
Smoking dependence is a complex habit with multiple factors contributing to the dependence profile, which varies between individuals. As far as the active tobacco alkaloids are concerned, nicotine is the most likely to cause dependence but others are certainly involved for some individuals. If a smoker still experiences cravings even when consuming a high strength of nicotine when using an e-cigarette, with all factors therefore seemingly well-replicated, and (importantly) a blood plasma nicotine test shows a sufficient level of nicotine (which we would judge to be at least 10ng/ml for reasonable efficacy), then clearly we are missing something. This occurs in a percentage of smokers attempting to switch. This missing component has often been shown to be the other WTAs in tobacco, the whole tobacco alkaloids nornicotine, anabasine, anatabine, and myosmine because adding Snus to the equation removes such cravings (since Snus is a whole tobacco product). Another method is to use a liquid refill that contains such WTAs, of which there are two brands currently, and many more will become available.
Some smokers can switch immediately with minor or no cravings, some take a week or two to get over the craving for the other WTAs, and some must employ Snus or WTA liquid refills, perhaps in the long term, in order to succeed. Opinions vary on the percentages of each group and there is no current agreement, but 25% of smokers attempting to switch to an ecig is a reasonable estimate of the number who will experience difficulties. One reason an e-cigarette may fail a particular individual is the lack of these WTAs, so it is something that can be resolved with a little application.
3. The commonly-available mini e-cigarette
Many smokers who attempt to convert to an electronic cigarette will start with a ‘mini’ e-cigarette that resembles a regular cigarette: a small 1st-generation model, with a refill liquid that may not suit them, of a nicotine strength that may be too low to prevent cravings. Multiple clinical trials have shown that naive users, isolated from expert advice, derived very little or even zero nicotine from such equipment.
It has been shown recently that higher levels of nicotine than are normally supplied with regular e-cigarette refills may be required in order to raise blood plasma nicotine levels sufficiently, for some individuals. While mini e-cigarettes may be sufficient for some smokers wishing to convert, it is clearly demonstrated that they are insufficient for a proportion of potential converts as they have limited performance (half or less that of the larger 2nd-gen models called ‘mid-size’ ecigs, and a fraction of 3rd-gen models such as variable voltage APVs, advanced personal vaporisers). We can show that 92% of long-term e-cigarette users upgrade to better-performing equipment, which by definition are of a larger format (the physical battery size is critical).
Within the e-cigarette community we have clearly demonstrated a difference in individual tolerance to nicotine of a factor of 10, so this needs to be taken into account. We have demonstrated that what suits one person may be ten times too low or too high for someone at the other end of the scale; a factor 5 difference at each end from the mean value.
Mentoring is therefore quite important as the initial experience may not be optimal. There are hundreds of different equipment options and thousands of different refills, and the initial choice is not usually successful as a long-term solution – the equipment and refills must fit the individual, not the other way around . We know that 92% of long-term users have upgraded their equipment and do not use a mini, and it can be assumed that virtually all will have changed their refill choice. We cannot underestimate the value of mentoring, even if via remote methods such as effective forum support.
It can be admitted that although e-cigarettes are provably highly effective, they are not a simple ‘buy-and-go’ option. Their principal drawback may well be that they need to be tuned to the individual, for optimal results and/or long-term success. In many cases the subject will find the optimal solution by trial and error, via research on the internet in many cases; in others, they may fail due to lack of support. It needs to be pointed out that although ‘gas station ecigs’ might work as a proof of concept, they are sub-optimal for successful smoking replacement. We are on 3rd-generation equipment now, and these obsolete 1st-gen models are fine for proof of concept use; they don’t work well enough, for most people, to be considered as an acceptable basis for either successful smoking replacement or clinical studies. They are proven not to work well by multiple clinical trials. The benchmark model now is the mid-size unit with a 650mAh to 1,000mAh battery, such as the eGo, Riva, Tornado or kGo models.
Mini ecigs are suitable for an introduction to the system; for proof-of-concept use; and for social smokers or other light users. The larger mid-size models are now the benchmark; have double the performance of the minis; and are the smallest units suitable for the average smoker. Heavy smokers may need an APV, as these have three times the performance of the minis.
E-Cigarette medical license for NRT use
It is expected that the first pharmaceutical license for e-cigarette use as an NRT will be issued in late 2013. The expected cost to the firm concerned is around £2.25m (for just the one single product), after three years of research, documentation and legal work, which explains why there are few takers for this option; and why there is huge resistance to this route since 99.99% of products will disappear, and the most effective hardware and refills would be among them.
Subsequently, we expect there to be a considerable reduction in the untrue propaganda about e-cigarettes since the offenders may face legal action.
And, of course, the people who fund the propaganda will be wanting to get in on the action. Hardly surprising, as whatever purpose might be claimed for e-cigarettes, they work orders of magnitude better than any current NRT whatever the purpose or function is defined as .
At Q3 2011 the number of UK smokers who had switched to an e-cigarette was 4%; by 2012 it was 6%; and by Q2 2013 the proportion is 8% or possibly a little higher. Already the action of smokers themselves has been several times more effective than NHS efforts in reducing the future death rate .
Given the considerable cost of the NHS Stop Smoking Services to the taxpayer, not to mention the fact that virtually all patients will return to smoking , many people feel that consumer Harm Reduction offers a far better deal. It would also help if elements within the Department of Health did not appear to be acting with the pharmaceutical industry to remove their commercial rivals; especially since the rivals in question will indisputably save a vast number more lives.
There is, naturally, opposition to the continued use of a tobacco product, nicotine or something that looks like smoking. When such opposition can be shown to be baseless on health grounds, it must then be asked: is the desired result a reduction in smoking-related sickness and death – or is it, instead, the cessation of leisure use of mild stimulants and stress-relievers for some non-health related reason, such as ideology or religious belief? Or more likely, commercial reasons?
A remarkable number of authors of medical papers condemning e-cigarettes turn out to have been funded by pharma corporates such as Pfizer, who strangely enough sell competing NRT products and drugs for treating sick smokers.
If the argument is strictly limited to the health issue, then there are no grounds whatsoever for restricting use of Snus (as has been proven) or e-cigarettes (as seems obvious). If the argument is about consumer products that may be stimulants or similar, and that are harmless with responsible consumption, then we are talking about also removing access to coffee, tea, chocolate, wine, beer, sherry and brandy. This does not seem likely to improve many people’s quality of life.
Snus research shows that a consumer of this Swedish processed oral tobacco can expect a shortening of their life by about four weeks, as against the 10 years suggested for a smoker. It’s quite likely that other dietary, lifestyle, work and environmental factors have far more negative influence than Snus; in e-cigarettes we expect to be looking at a similar situation: nothing worth worrying about. When compared with smoking, the issue is likely invisible.
So, we can sum up with:
- There is no clinical reason to restrict the use of e-cigarettes
- Restricting access to e-cigarettes will condemn many inveterate smokers to death
- Prof Britton of the RCP says that many millions of lives could be saved if smokers switch (just in the UK)
- Restricting access to e-cigarettes will prevent many smokers switching who might avoid sickness and death
- It has been estimated that, eventually, e-cigarettes could reduce the smoking death rate by more than 50% in some countries
- Most of those responsible for opposition to e-cigarettes appear to be financially conflicted, since their employment or funding depends in some way on the pharmaceutical industry, who are desperate to have e-cigarettes removed from the market
- Anti-ecigarette ‘research’ qualifies as some of the worst junk science produced in any arena
- A close examination of anti-ecigarette press releases and the clinical data they are supposed to depend on often reveals significant differences between the PR and the data; in effect, the PR consists of lies
- E-cigarettes depend for efficacy on free choice by the consumer, since there is no one-size-fits-all solution
- An e-cigarette may not be the perfect choice for some individuals
 Snus is a specially-processed Swedish form of oral tobacco (‘smokeless tobacco’) that is usually sold in tins of very small packets that resemble tiny, flat teabags. The processing is a form of steam treatment sometimes referred to (rightly or wrongly) as ‘pasteurising’, that removes the majority of the carcinogens, although significant amounts remain.
It can be referred to as ‘spitless’ or ‘non-chewing’ tobacco because it is invisible in use, and no extra saliva is produced. A packet is inserted behind the upper lip (not lower), and disposed of after 45 minutes or so.
This substitute for cigarettes is very popular in Sweden, where they reduced the number of smokers by 50% by promoting its availability as a consumer Harm Reduction product. The smoking-related death rate fell in parallel, with the result that Sweden has the lowest smoking-related mortality rate of any developed country by a wide margin. The only comparable results are in other Scandinavian countries where Snus is also used.
Sweden has the lowest male lung cancer and oral cancer rate in Europe.
Although some carcinogens are left by the steam processing (c. 1,000 – 2,000ng/gm) the amounts remaining are not cancer-promoting because the epidemiology shows otherwise: oral cancer rates fell as Snus use increased, and Sweden now has the lowest male oral cancer figures in the EU.
In addition, the very large amount of clinical study data available clearly shows this. It is said that the most cancer-forming of all chewing tobaccos is still 4 times less likely to cause oral cancer than smoking, but Snus has no identifiable risk of oral cancer [1a].
[1a] Analysis by Profs. Phillips and Rodu:
 When pharmaceutical NRTs were licensed for long-term use in the UK recently, the only source of safety data that could be referenced was the Snus research from Sweden, which was used as the basis for the safety analysis. There is no other large-scale data for long-term consumption of nicotine without smoke. Long-term NRT studies are tiny in comparison and of shorter timescales: NICE say they have 5 years’ data.
Because the facts (Swedish disease and death stats) prove that long-term nicotine use poses no significant risk, together with the huge amount of data that tells the same story, NRTs were successfully licensed as long-term treatments. It is reported that a smoker can expect an average reduction in life expectancy of 10 years, a Snus user about 4 weeks.
The Snus data has been collected over 25 years, includes more than 150 clinical studies, and has cohorts of tens of thousands of subjects. It clearly shows that Snus consumption is not only safer than smoking but it is safe in absolute terms. The giant-scale meta-analyses of 62 and 89 trials carried out by Lee and Hamlin showed that a Snus user has no elevation of risk for any type of cancer, heart disease or vascular disease. The difference between a Snus user and a non-smoker is not statistically significant for any type of disease in total (rr=1.1). A Snus user has virtually the same risk as a non-smoker (that is, a smoker who has totally quit). There are individual trials with contrary results (example: for cancer of the pancreas), but these must be weighed against 150 trials showing no identifiable risk [2a]. However, a slight elevation for risk of stroke cannot be ruled out, and Snus use appears to be strongly associated with a reduction in life expectancy of around 4 weeks.
[2a] Lee, Hamling: Smokeless tobacco US and SE, meta-analysis of 89 trials:
 Snus is assumed to have been banned in the EU  because of the impact a safe form of tobacco use has on the income of the pharmaceutical industry, since the consumption of Snus is proven to have no significant health implications. Pharma loses in two ways:
- Sales of NRTs and other quit-smoking drugs are hit very hard indeed. This is a $4billion global market and one that pharma will fight hard to protect.
- Sales of chemotherapy drugs, COPD drugs, cardiac drugs, vascular drugs and other therapies for sick and dying smokers are believed to value as much as 25 times the NRT market (somewhere around $100bn annually). Obviously, if the smoking death rate falls by 50%, the sales of these drugs are likely to fall in parallel.
- Sales of NRTs and chemotherapy drugs etc. are particularly poor in Sweden, and the pharmaceutical industry is keen to ensure this does not spread.
This is the most serious threat to pharmaceutical industry income that has ever been seen, and they have fought very hard to oppose e-cigarettes, even obtaining bans in some countries despite there not being a shred of evidence that e-cigarettes pose any risk.
 PG research stretches back to the 1940s, and no person has ever died from its use. It is the main excipient in some nebulisers given to lung transplant patients, and is regarded as inert. Note that it is also used as the diluent in injectable medicines that are immiscible, such as diazepam, and is therefore approved for direct injection into the bloodstream. It is the main ingredient in theatrical/disco fog and is approved under all employment law for long-term high-volume inhalation by employees. Here are around 40 references:
The relevant characteristics of PG are:
1. It is generally regarded as inert or nearly inert for all forms of consumption including injection, inhalation and ingestion.
2. It has a powerful bactericidal and virucidal action when dispersed as an aerosol.
3. It has no implications for health except for some intolerance by individuals (>1, <10 ex 100).
4. The only likely effect of exposure to aerosols is the drying action on mucosa due to its humectant effect.
5. There are no recorded instances of death or severe harm.
 ref #2 @ http://www.eccauk.org/index.php/nhs-quit-smoking-fail.html
 Check British Pharmacopeia for full lists of ingredients including excipients and diluents, these are not usually included in MIMS. Search: propylene glycol BP and glycerine BP. Also see:
Vansickel A. R., Blank M., Cobb C., Kilgalen B., Austin J., Weaver M. et al. Clinical laboratory model for evaluating the effects of electronic ‘cigarettes’. February 2011; 17th Annual Meeting of the Society for Research on Nicotine and Tobacco. Toronto, Canada, 2011.
 Rodu: http://rodutobaccotruth.blogspot.com
Phillips, Rodu: http://www.tobaccoharmreduction.org
Rodu, Cole: http://smokersonly.org